8-K: Zynex Reports 11% Revenue Increase in Second Quarter, Revises Full-Year Guidance

Zynex, Inc. announced an 11% year-over-year revenue increase for the second quarter of 2024, reaching $49.9 million, while also revising its full-year revenue guidance due to strategic shifts.

Summary

• Zynex reported a revenue of $49.9 million for the second quarter of 2024, an 11% increase compared to $45.0 million in the same quarter of the previous year.
• The company's order volume increased by 20% year-over-year, marking the highest number of orders in company history for the ninth consecutive quarter.
• Net income for the quarter was $1.2 million, or $0.04 per diluted share, down from $3.4 million, or $0.09 per diluted share, in the second quarter of 2023.
• Cash flow from operations for the first six months of 2024 was $3.2 million, a 20% increase year-over-year.
• Zynex repurchased $2.2 million of its common stock in the second quarter, and $70 million over the last twenty-four months.
• The company has revised its full-year 2024 revenue guidance to an approximate 9% increase compared to 2023, down from previous expectations.
• Third quarter 2024 revenue is estimated to be at least $50.0 million, with diluted EPS estimated to be at least $0.05.
• The company expects 2024 net revenue of at least $200 million, with diluted EPS expected to be at least $0.20 per share.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company shows growth in orders and revenue, the reduced guidance and lower net income temper the positive aspects. The strategic shift towards profitable growth is a positive long-term move, but the short-term impact is a reduction in revenue.

Positives

• Zynex achieved a 20% year-over-year increase in order volume, demonstrating strong demand for its products.
• The company's cash flow from operations increased by 20% year-over-year, indicating improved operational efficiency.
• Zynex continued its share repurchase program, returning capital to shareholders.
• Gross profit margin improved to 80% of revenue, up from 79% in the same quarter last year.
• The company is focusing on profitable growth and sales rep productivity, which is expected to strengthen its position moving forward.

Negatives

• Second quarter revenue was lower than previous guidance, primarily due to a reduction in sales representatives and a change in product mix.
• Net income decreased to $1.2 million, down from $3.4 million in the same quarter of the previous year.
• Adjusted EBITDA decreased to $3.5 million, compared to $4.0 million in the same quarter of the previous year.
• The company revised its full-year revenue guidance down to a 9% increase, indicating a slowdown in expected growth.
• The change in product mix towards private labeled pain management products, which are one-time sales, impacts the trailing revenue model.

Risks

• The company's revenue is impacted by changes in product mix, with a shift towards one-time sales of private labeled products.
• The reduction in sales representatives, while aimed at improving productivity, has negatively impacted near-term revenue.
• The company's future performance is subject to risks related to obtaining regulatory approvals for new products.
• The company is dependent on reimbursement for its products from health insurance companies.
• The company is dependent on third party manufacturers to produce its products on time and to specifications.

Future Outlook

Zynex expects 2024 net revenue to increase approximately 9% compared to 2023, with a return to normal top-line growth of approximately 20% in the pain management division in 2025. Third quarter 2024 revenue is estimated to be at least $50.0 million, with diluted EPS estimated to be at least $0.05. The company expects 2024 net revenue of at least $200 million, with diluted EPS expected to be at least $0.20 per share.

Management Comments

• The second quarter of 2024 was highlighted by a strong cadence of order growth and revenue as we work toward FDA approvals of next-generation devices and launch of new pain management products, said Thomas Sandgaard, President and CEO of Zynex.
• As we have evolved from a small company prior to 2017 to expected revenues of roughly $200 million in 2024, we have taken additional steps during recent quarters to enable us to grow smoothly to a $1 billion company in the longer term.
• In the second quarter, increasing sales and profitable growth for our pain management division delivered a 20% improvement in orders year-over-year.
• With the change in product mix and sales force reduction, we are revising guidance down for the year.
• Looking ahead, we continue to focus on diversifying revenue streams with innovative new products and ensuring sustained growth as we build on our holistic, non-invasive approach to pain management.

Industry Context

The medical device industry is competitive, with companies constantly innovating and seeking regulatory approvals for new products. Zynex's focus on non-invasive pain management aligns with a growing trend towards less invasive treatment options. The company's shift in product mix and focus on profitable growth reflects a strategic response to market dynamics.

Comparison to Industry Standards

• Zynex's 11% revenue growth is moderate compared to some high-growth medical device companies, but it is important to consider the company's strategic shift towards profitable growth.
• Companies like Nevro Corp (NVRO) and InMode Ltd (INMD) have shown higher growth rates in recent periods, but they also operate in different segments of the medical device market.
• Zynex's gross profit margin of 80% is strong and indicates efficient cost management, which is comparable to other established medical device companies.
• The company's focus on sales rep productivity and strategic product mix changes is a common approach in the industry to optimize profitability and long-term growth.

Stakeholder Impact

• Shareholders may be concerned about the reduced revenue guidance and lower net income.
• Employees may be affected by the reduction in sales representatives.
• Customers may benefit from the company's focus on innovative new products.
• Suppliers may see changes in demand due to the shift in product mix.

Next Steps

• The company will continue to work towards FDA approvals of next-generation devices.
• Zynex will focus on the launch of new pain management products.
• The company will continue to focus on diversifying revenue streams with innovative new products.
• Zynex will continue to emphasize profitable growth and sales rep productivity.

Key Dates

Keywords

medical devices, pain management, rehabilitation, revenue, net income, EBITDA, stock repurchase, sales growth, financial results, guidance